

# 10.20 1230ConnerB Reeves et al MS IX

Current run (last updated Oct 25, 2016 9:00am)


20

Polls

21

Participants


## What type of Life Sciences Company do you represent (check all that apply)?



Response options	Count	Percentage
<b>Pharmaceutical</b>	7	78%
Medical Device	1	11%
Other	1	11%

9 Responses


## What is the size of your company (by total revenue)?



Response options	Count	Percentage
<\$1Billion	3	23%
\$1-\$2 Billion	2	15%
\$2-\$10 Billion	1	8%
>\$10 Billion	7	54%

13 Responses


## What Status applies to your Company?



Response options	Count	Percentage
Currently Under a CIA	5	25%
Previously Under a CIA	5	25%
<b>Neither</b>	<b>10</b>	<b>50%</b>

20 Responses


**Do you allow your Medical Affairs organization to provide proactive disease education to HCPs?**



Response options	Count	Percentage
Yes	15	100%
No	0	0%

**15**  
Responses


**Does the current strategy for your Commercial activity align with the Medical Affairs Department?**



Response options	Count	Percentage
Yes	13	100%
No	0	0%

**13**  
Responses


**If Commercial and Medical align on strategic planning, does it cover specific issues as: (Please select all that apply)**



Response options	Count	Percentage
Publications Planning	0	0%
Medical Information Responses	0	0%
Advisory Boards	0	0%
Grant Requests	0	0%
HCP Communications	0	0%

**0**  
Responses

**Management and engagement with Key Opinion Leaders- who owns the relationship?**




Response options	Count	Percentage
Commercial	0	0%
Medical	0	0%
Both	0	0%
Other	0	0%

**0**  
Responses

### Does your Company currently use Nurse Educators?

Response options


Percentage



Response options	Count	Percentage
No	0	0%
Yes, and they are part of the Commercial Organization	0	0%
Yes, and they are part of Medical Affairs	0	0%
Yes, but in Other Department	0	0%

0 Responses


### Does your company have a formal definition (e.g. in a policy or other guidance document) for the term "scientific exchange"?



Response options	Count	Percentage
Yes, Single Definition	0	0%
Yes, More than One	0	0%
No/don't know or informal definition	0	0%

0 Responses


### Does your company permit Medical Affairs personnel to present to payor/managed care organizations?



Response options	Count	Percentage
No	0	0%
Yes, with Commercial Teams	0	0%
Yes, Separate from Commercial Teams	0	0%

0 Responses


### Where does the Health Economics function report within your organization? (Please select all that apply)



Response options	Count	Percentage
Medical	0	0%
Commercial	0	0%
R&D	0	0%
Other	0	0%

0 Responses


**Does your company engage in discussions they believe are covered by the FDAMA 114 safe harbor (i.e. HEOR-based promotional discussions)?**



Response options	Count	Percentage
Yes	0	0%
No	0	0%

**0**  
Responses


**Do you have a policy/internal guidance document that governs these types of interactions?**



Response options	Count	Percentage
Yes	0	0%
No	0	0%
Don't know or not applicable	0	0%

**0**  
Responses


**Does compliance have responsibility for oversight or management of these types of interactions?**



Response options	Count	Percentage
Yes	0	0%
No	0	0%

**0**  
Responses


**Does Commercial have a role in planning/directing HEOR analysis?**



Response options	Count	Percentage
Yes	0	0%
No	0	0%
Don't know	0	0%

**0**  
Responses


### In response to the court decisions regarding the First Amendment, what changes in compliance rules is your company considering?



Response options	Count	Percentage
No change	0	0%
Pre-Clear Off Label before use	0	0%
Allow use of truthful Off-Label	0	0%
Other	0	0%

0 Responses


### What is your organization's response to the BIO-PhRMA Principles on Responsible Sharing of Truthful and Non-Misleading Information About Medicines with Health Care Professionals and Payers?



Response options	Count	Percentage
Involvement in Creation	0	0%
Awareness	0	0%
Adoption	0	0%
Ignorance	0	0%

0 Responses


### Impact of 1st Amendment cases/BIO-PhRMA Principles on policies/practices related to responding to unsolicited questions in group settings?



Response options	Count	Percentage
No change	0	0%
Allow use of truthful Off-Label response	0	0%
Don't know	0	0%

0 Responses


### Changes in approach to communications about pipeline products?



Response options	Count	Percentage
No change	0	0%
Allow use of truthful Off-Label response	0	0%
Don't know	0	0%

0 Responses

# Pressure from commercial/medical based on activities of competitors regarding med affairs/ML activities?



Response options	Count	Percentage
Feel the heat	0	0%
No change	0	0%
Other	0	0%

**0**  
Responses